A case of pancytopenia

Journal of Psychopharmacology

Volumn 20, Issue 5, 2006, Pages 690-692

  Keown, Patrick ^a   McAllister Williams, Hamish ^a   Young, Allan ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Adverse effects; Haematopoiesis; Pancytopenia; Valproic acid

Indexed keywords

CITALOPRAM; FLUPENTIXOL; OLANZAPINE; PROCYCLIDINE; RISPERIDONE; VALPROIC ACID;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CONFUSION; DISEASE ASSOCIATION; HUMAN; LABORATORY TEST; MALE; MEGALOCYTOSIS; PANCYTOPENIA; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTICONVULSANTS; FOLIC ACID; HUMANS; MALE; PANCYTOPENIA; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VALPROIC ACID; VITAMIN B 12;

EID: 33748189394     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881106065101     Document Type: Article

References (7)

1. Acharya S, Bussel J B (2000) Hematologic toxicity of sodium valproate. Journal of Pediatric Hematology/Oncology 22: 62-65
2. Ravindran A, Silverstone P, Lacroix D, Van Schaick E, Vermeulen A, Alexander J (2004) Risperidone does not affect steady-state pharmacokinetics of divalproex sodium in patients with bipolar disorder. Clinical Pharmacokinetics 43: 733-740.
3. Goodwin G (2003) Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 17: 149-173
4. May R, Sunder T R (1993) Hematologic manifestations of long-term valproate therapy. Epilepsia 34: 73-76
5. Ravindran (2000) Observational, open, parallel-group trial to document the steady state pharmacokinetics and safety of valproate with risperidone or placebo in 24 adult bipolar patients
6. Regier D A, Farmer M E, Rae D S, Locke B Z, Keith S J, Judd L L, Goodwin F K (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Results from the epidemiologic Catchment Area (ECA) Study. JAMA 264: 2511-2518
7. Vasudev K, Goswami U, Kohli K (2000) Carbamazapine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology 150: 15-23